JP6849683B2 - 低酸素関連疾患の治療のための医薬組成物及び方法 - Google Patents

低酸素関連疾患の治療のための医薬組成物及び方法 Download PDF

Info

Publication number
JP6849683B2
JP6849683B2 JP2018530677A JP2018530677A JP6849683B2 JP 6849683 B2 JP6849683 B2 JP 6849683B2 JP 2018530677 A JP2018530677 A JP 2018530677A JP 2018530677 A JP2018530677 A JP 2018530677A JP 6849683 B2 JP6849683 B2 JP 6849683B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hypoxia
tpn
alginate
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018530677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527407A (ja
JP2018527407A5 (enExample
Inventor
ヨリ アッペルバウム，エラシュミエル
ヨリ アッペルバウム，エラシュミエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018527407A publication Critical patent/JP2018527407A/ja
Publication of JP2018527407A5 publication Critical patent/JP2018527407A5/ja
Application granted granted Critical
Publication of JP6849683B2 publication Critical patent/JP6849683B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018530677A 2015-08-24 2016-09-13 低酸素関連疾患の治療のための医薬組成物及び方法 Active JP6849683B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562208914P 2015-08-24 2015-08-24
PCT/US2016/051482 WO2017035542A1 (en) 2015-08-24 2016-09-13 Pharmaceutical compositions and methods for the treatment of hypoxia-related diseases

Publications (3)

Publication Number Publication Date
JP2018527407A JP2018527407A (ja) 2018-09-20
JP2018527407A5 JP2018527407A5 (enExample) 2020-02-13
JP6849683B2 true JP6849683B2 (ja) 2021-03-24

Family

ID=58101120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018530677A Active JP6849683B2 (ja) 2015-08-24 2016-09-13 低酸素関連疾患の治療のための医薬組成物及び方法

Country Status (8)

Country Link
US (1) US10653685B2 (enExample)
EP (1) EP3340985B1 (enExample)
JP (1) JP6849683B2 (enExample)
CN (1) CN108076628A (enExample)
AU (1) AU2016311504A1 (enExample)
CA (1) CA2996614C (enExample)
IL (1) IL257689B (enExample)
WO (1) WO2017035542A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246503A1 (en) * 2021-05-24 2022-12-01 The Florey Institute Of Neuroscience And Mental Health Methods for mediating vasoconstriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89349A0 (en) * 1989-02-20 1989-09-10 Hadassah Medical Organisation Pharmaceutical composition for protecting the heart comprising a heterocyclic ethylenediamine derivative and methods for the use thereof
IL155111A0 (en) * 2003-03-27 2003-10-31 Yerachmiel Yori Applebaum Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof
EP1620140B1 (en) 2003-05-05 2013-10-09 Ben-Gurion University Of The Negev Research And Development Authority Injectable cross-linked polymeric preparations and uses thereof
EP2476411A1 (en) * 2007-03-13 2012-07-18 Biolinerx Ltd. A method of promoting tissue repair
US20120276152A1 (en) * 2011-04-29 2012-11-01 Syed Hossainy Systems and methods of using zinc-chelator to treat myocardial infarction
WO2013003445A1 (en) 2011-06-30 2013-01-03 Athena Cardionet Ltd. Tetra-pyridine compounds and composition for protecting cells, tissues and organs against ischemia-reperfusion injury

Also Published As

Publication number Publication date
WO2017035542A1 (en) 2017-03-02
IL257689B (en) 2021-03-25
JP2018527407A (ja) 2018-09-20
US10653685B2 (en) 2020-05-19
EP3340985B1 (en) 2020-11-25
CN108076628A (zh) 2018-05-25
CA2996614C (en) 2023-12-12
AU2016311504A1 (en) 2018-03-08
US20180243276A1 (en) 2018-08-30
CA2996614A1 (en) 2017-03-02
EP3340985A1 (en) 2018-07-04
IL257689A (en) 2018-04-30
EP3340985A4 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
ES2909071T3 (es) Posología para ponesimod, un agonista selectivo del receptor de S1P1
US12076340B2 (en) Use of trientine to deliver copper to ischemic tissue
US10925890B2 (en) Use of dextran sulfate
JP6849683B2 (ja) 低酸素関連疾患の治療のための医薬組成物及び方法
WO2016110225A1 (zh) 一种磺酰胺类药物组合物
JP2014526518A (ja) 心不全またはニューロン損傷を治療するための化合物およびその方法
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN117257803B (zh) 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用
CN113975276B (zh) 考比替尼在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
TW202339711A (zh) 預防或治療心血管疾病的高穿透性的阿司匹靈和其他非類固醇抗發炎藥的前藥
EP3763362B1 (en) Method of treating idiopathic pulmonary fibrosis
JP2012522770A (ja) 急性心筋梗塞に対する初期対応におけるリボースの使用
WO2016074203A1 (zh) 包含二氧化氯的细胞凋亡诱导剂及其在制备化妆品或抗衰老或抗肿瘤药物中的用途
CN120459270A (zh) OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用
CN120603579A (zh) 新型溶液
BR112018005638B1 (pt) Composição farmacêutica que compreende tetramina quelante de cobre e íon de cobre, uso da composição farmacêutica para aumentar o nível de cobre intracelular em um tecido isquêmico e kit

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190912

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201014

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20201119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210304

R150 Certificate of patent or registration of utility model

Ref document number: 6849683

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250